CN
CNTA
Centessa Pharmaceuticals plc
$39.78
+0.08%
$6.2B
No data for this timeframe.
Vol
Market Cap$6.2B
Cap SizeMid Cap
Analyst ConsensusHold (47%)
Inst. Holders6 funds
Inst. Value$284.1M
Inst. Activity4 buys / 0 sells
Insider Activity0B / 9S
Insider Net $-$12.3M
SEC Reports4
Recent Activity
May 12, 2026
earnings_calendar
CNTA Q1 2026 Earnings Scheduled — 2026-05-12
May 1, 2026
Insider
Accardi Mario Alberto sold 604 shares
Chief Executive Officer @ $39.42 ($23.8K)
Apr 17, 2026
SEC
Centessa Pharmaceuticals (CNTA) is being acquired by Eli Lilly (LILY) in a $7.8B deal structured as a Scheme of Arrangem
PREM14A — Impact 9/10
Apr 13, 2026
SEC
Centessa Pharmaceuticals is soliciting shareholder approval for its acquisition by Eli Lilly, expected to close in Q3 20
DEFA14A — Impact 8/10
Mar 26, 2026
Insider
Anderson Karen M. sold 41,076 shares
Chief People Officer @ $0.00 ($0.00)
Mar 26, 2026
Insider
Weinhoff Gregory M sold 23,998 shares
Chief Business Officer @ $3.85 ($92.4K)
Mar 16, 2026
SEC
Centessa Pharmaceuticals C-suite executives sold over $7.2M in stock within a week, primarily from Chief People Officer
CLUSTER — Impact 7/10
Inst.
FMR LLC — ADD
8,961,939 shares ($224.1M)
Price Targets
$44.57
+12.0% upside
Buy
Current $39.78
Low $38.00
Median $42.00
High $62.00
7 analysts
$38.00
$62.00
Analyst Ratings
4Strong Buy
5Buy
10Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 20, 2026 | Wells Fargo | DOWNGRADE | Overweight → Equal-Weight |
| Apr 2, 2026 | Guggenheim | DOWNGRADE | Buy → Neutral |
| Apr 1, 2026 | Leerink Partners | DOWNGRADE | Outperform → Market Perform |
| Mar 31, 2026 | Wolfe Research | DOWNGRADE | Outperform → Peer Perform |
| Mar 31, 2026 | Needham | DOWNGRADE | Buy → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.40 ▲ +23.9% | $-0.53 — $-0.30 | -6% YoY | 6 |
| Next Q | $-0.42 ▲ +24.2% | $-0.55 — $-0.31 | -2% YoY | 6 |
| Current FY | $-1.56 ▲ +11.4% | $-1.56 — $-1.56 | -7% YoY | 1 |
| Next FY | $-1.90 | $-2.77 — $-1.30 | -22% YoY | 9 |
Latest Reports
BULLISH
PREM14A
9/10
Centessa Pharmaceuticals (CNTA) is being acquired by Eli Lilly (LILY) in a $7.8B deal structured as a Scheme of Arrangem
Apr 17, 2026
BULLISH
DEFA14A
8/10
Centessa Pharmaceuticals is soliciting shareholder approval for its acquisition by Eli Lilly, expected to close in Q3 20
Apr 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $224.1M | ADD |
| MORGAN STANLEY | $27.7M | TRIM |
| BANK OF AMERICA CORP | $23.7M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $7.0M | ADD |
| TWO SIGMA INVESTMENTS, LP | $1.4M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | Accardi Mario | F | $23.8K |
| Mar 26, 2026 | Anderson Karen | M | $0.00 |
| Mar 26, 2026 | Weinhoff Gregory | M | $92.4K |
| Mar 26, 2026 | Weinhoff Gregory | SELL | $719.9K |
| Mar 26, 2026 | Weinhoff Gregory | M | $0.00 |
6 institutional holders with $284.1M total value (11,360,712 shares) as of 2025-Q4. Top holders: FMR, MORGAN, BANK. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 8,961,939 | $224.1M | 78.9% | ADD +42.8% |
| 2 | MORGAN STANLEY | 1,109,098 | $27.7M | 9.8% | TRIM -37.3% |
| 3 | BANK OF AMERICA CORP /DE/ | 949,544 | $23.7M | 8.4% | ADD +71.7% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 279,300 | $7.0M | 2.5% | ADD +69.7% |
| 5 | TWO SIGMA INVESTMENTS, LP | 57,444 | $1.4M | 0.5% | DOUBLED +371.5% |
| 6 | WELLS FARGO & COMPANY/MN | 3,387 | $84.7K | 0.0% | ADD +42.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 6,277,243 | 8,961,939 | +42.8% | $224.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 553,007 | 949,544 | +71.7% | $23.7M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 164,600 | 279,300 | +69.7% | $7.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 2,379 | 3,387 | +42.4% | $84.7K | 2025-Q4 |
| FMR LLC | ADD | 3,826,194 | 6,277,243 | +64.1% | $152.2M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 1,793,471 | 1,124,445 | -37.3% | $27.3M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 135,798 | 553,007 | +307.2% | $13.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 384,900 | 164,600 | -57.2% | $4.0M | 2025-Q3 |
| UBS Group AG | TRIM | 255,050 | 130,478 | -48.8% | $3.2M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 150 | 2,379 | +1486.0% | $57.7K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 2,937,467 | 1,793,471 | -38.9% | $23.6M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 178,000 | 384,900 | +116.2% | $5.1M | 2025-Q2 |
| UBS Group AG | DOUBLED | 73,483 | 255,050 | +247.1% | $3.4M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 207,028 | 135,798 | -34.4% | $1.8M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 15,300 | 72,144 | +371.5% | $948.0K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 31,446 | 150 | -99.5% | $2.0K | 2025-Q2 |
| MORGAN STANLEY | ADD | 1,924,509 | 2,937,467 | +52.6% | $42.2M | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 1,070,209 | 73,483 | -93.1% | $1.1M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEW | — | 31,446 | — | $452.2K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 37,900 | 15,300 | -59.6% | $220.0K | 2025-Q1 |
| MORGAN STANLEY | ADD | 1,379,651 | 1,924,509 | +39.5% | $32.2M | 2024-Q4 |
| UBS Group AG | DOUBLED | 5,007 | 1,070,209 | +21274.3% | $17.9M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 2,050,392 | 1,379,651 | -32.7% | $22.1M | 2024-Q3 |
8 unique insiders with 9 transactions. Net insider value: -$12.3M ($0.00 bought, $12.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | Accardi Mario Alberto | Chief Executive Officer | F | 604 | $39.42 | $23.8K |
| Mar 26, 2026 | Anderson Karen M. | Chief People Officer | M | 41,076 | $0.00 | $0.00 |
| Mar 26, 2026 | Weinhoff Gregory M | Chief Business Officer | M | 23,998 | $3.85 | $92.4K |
| Mar 26, 2026 | Weinhoff Gregory M | Chief Business Officer | SELL | 23,998 | $30.00 | $719.9K |
| Mar 26, 2026 | Weinhoff Gregory M | Chief Business Officer | M | 23,998 | $0.00 | $0.00 |
| Mar 26, 2026 | Anderson Karen M. | Chief People Officer | M | 41,076 | $8.01 | $329.0K |
| Mar 26, 2026 | Anderson Karen M. | Chief People Officer | SELL | 41,076 | $30.12 | $1.2M |
| Mar 17, 2026 | Anderson Karen M. | Chief People Officer | SELL | 10,043 | $28.10 | $282.2K |
| Mar 17, 2026 | Anderson Karen M. | Chief People Officer | M | 10,043 | $0.00 | $0.00 |
| Mar 17, 2026 | Anderson Karen M. | Chief People Officer | M | 10,043 | $4.01 | $40.3K |
| Mar 16, 2026 | Anderson Karen M. | Chief People Officer | M | 64,768 | $0.00 | $0.00 |
| Mar 16, 2026 | Anderson Karen M. | Chief People Officer | SELL | 64,768 | $28.21 | $1.8M |
| Mar 16, 2026 | Anderson Karen M. | Chief People Officer | M | 64,768 | $4.01 | $259.7K |
| Mar 13, 2026 | Weinhoff Gregory M | Chief Business Officer | SELL | 61,253 | $26.17 | $1.6M |
| Mar 13, 2026 | Anderson Karen M. | Chief People Officer | M | 94,224 | $4.01 | $377.8K |
| Mar 13, 2026 | Anderson Karen M. | Chief People Officer | SELL | 107,961 | $26.15 | $2.8M |
| Mar 13, 2026 | Anderson Karen M. | Chief People Officer | M | 94,224 | $0.00 | $0.00 |
| Mar 13, 2026 | Anderson Karen M. | Chief People Officer | M | 109,398 | $4.01 | $438.7K |
| Mar 13, 2026 | Anderson Karen M. | Chief People Officer | M | 109,398 | $0.00 | $0.00 |
| Mar 13, 2026 | Anderson Karen M. | Chief People Officer | SELL | 107,961 | $26.15 | $2.8M |
| Feb 2, 2026 | Kanes Stephen | Chief Medical Officer | A | 120,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Weinhoff Gregory M | Chief Business Officer | A | 31,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Weinhoff Gregory M | Chief Business Officer | A | 123,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Deferiere Raphael | Chief Accounting Officer | A | 11,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Deferiere Raphael | Chief Accounting Officer | A | 42,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Crowley John J | Chief Financial Officer | A | 45,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Crowley John J | Chief Financial Officer | A | 181,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Anderson Karen M. | Chief People Officer | A | 29,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Anderson Karen M. | Chief People Officer | A | 117,000 | $0.00 | $0.00 |
| Feb 2, 2026 | HUSSAIN IQBAL J | Chief Legal Officer | SELL | 38,951 | $25.15 | $979.7K |
| Feb 2, 2026 | HUSSAIN IQBAL J | Chief Legal Officer | A | 40,000 | $0.00 | $0.00 |
| Feb 2, 2026 | HUSSAIN IQBAL J | Chief Legal Officer | A | 160,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Bush Tia L | Chief Technology & Quality Ofc | A | 35,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Bush Tia L | Chief Technology & Quality Ofc | A | 140,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Accardi Mario Alberto | Chief Executive Officer | A | 68,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Accardi Mario Alberto | Chief Executive Officer | A | 273,000 | $0.00 | $0.00 |
| Feb 1, 2026 | Weinhoff Gregory M | Chief Business Officer | F | 14,158 | $24.57 | $347.9K |
| Feb 1, 2026 | Anderson Karen M. | Chief People Officer | F | 10,606 | $24.57 | $260.6K |
| Feb 1, 2026 | HUSSAIN IQBAL J | Chief Legal Officer | F | 7,780 | $24.57 | $191.2K |
| Feb 1, 2026 | Bush Tia L | Chief Technology & Quality Ofc | F | 8,549 | $24.57 | $210.0K |
| Feb 1, 2026 | Accardi Mario Alberto | Chief Executive Officer | F | 2,915 | $24.57 | $71.6K |
| Jan 30, 2026 | HUSSAIN IQBAL J | Chief Legal Officer | SELL | 1,010 | $25.01 | $25.3K |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 2 bearish, 0 mixed, 0 neutral. Avg impact: 7.5/10.
BULLISH
PREM14A
9/10
Centessa Pharmaceuticals (CNTA) is being acquired by Eli Lilly (LILY) in a $7.8B deal structured as
Apr 17, 2026
BULLISH
DEFA14A
8/10
Centessa Pharmaceuticals is soliciting shareholder approval for its acquisition by Eli Lilly, expect
Apr 13, 2026
BEARISH
CLUSTER
7/10
Centessa Pharmaceuticals C-suite executives sold over $7.2M in stock within a week, primarily from C
Mar 16, 2026
BEARISH
CLUSTER
6/10
Centessa Pharmaceuticals insiders executed a significant share disposition cluster within one day, l
Mar 13, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (47% buy). Based on 19 analysts: 4 strong buy, 5 buy, 10 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$44.57 mean target
+12.0% upside
Buy (2.46)
$38.00 Low
$62.00 High
| Metric | Value |
|---|---|
| Current Price | $39.78 |
| Target Low | $38.00 |
| Target Mean | $44.57 |
| Target Median | $42.00 |
| Target High | $62.00 |
| # Analysts | 7 |
| Recommendation | Buy (2.46) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.40 | $-0.53 | $-0.30 | -6.1% | +23.9% | 2↑ 1↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.42 | $-0.55 | $-0.31 | -1.6% | +24.2% | 2↑ 1↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-1.56 | $-1.56 | $-1.56 | -6.9% | +11.4% | 1↑ 2↓ | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$-1.90 | $-2.77 | $-1.30 | -21.6% | -0.1% | 1↑ 3↓ | $0.0B | 0.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.403 | |
| 7d ago | $-0.422 | +0.019 |
| 30d ago | $-0.530 | +0.127 |
| 60d ago | $-0.392 | -0.012 |
| 90d ago | $-0.409 | +0.005 |
9 analyst firms have rated this stock: 0 upgrades, 5 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 20, 2026 | Wells Fargo | DOWNGRADE | Overweight | Equal-Weight |
| Apr 2, 2026 | Guggenheim | DOWNGRADE | Buy | Neutral |
| Apr 1, 2026 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Mar 31, 2026 | Wolfe Research | DOWNGRADE | Outperform | Peer Perform |
| Mar 31, 2026 | Needham | DOWNGRADE | Buy | Hold |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Jan 29, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 2, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 2, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 10, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Dec 1, 2025 | B. Riley Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 4 | 5 | 10 | 0 | 0 | 47% | |
| Apr 1, 2026 | 6 | 8 | 5 | 0 | 0 | 74% | |
| Mar 1, 2026 | 8 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 7 | 13 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 7 | 13 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings_calendar
CNTA Q1 2026 Earnings Scheduled — 2026-05-12
Apr 17, 2026
short_interest
FTD: CNTA — 39,776 shares ($1.6M) failed to deliver
Settlement: 20260417, Price: $39.53, FTD Value: $1,572,345.28, CENTESSA PHARMACEUTICALS PLC S
Apr 16, 2026
short_interest
FTD: CNTA — 39,776 shares ($1.6M) failed to deliver
Settlement: 20260416, Price: $39.61, FTD Value: $1,575,527.36, CENTESSA PHARMACEUTICALS PLC S
Apr 2, 2026
short_interest
FTD: CNTA — 221,240 shares ($8.8M) failed to deliver
Settlement: 20260402, Price: $39.86, FTD Value: $8,818,626.4, CENTESSA PHARMACEUTICALS PLC S
Apr 1, 2026
short_interest
FTD: CNTA — 384,340 shares ($15.3M) failed to deliver
Settlement: 20260401, Price: $39.72, FTD Value: $15,265,984.8, CENTESSA PHARMACEUTICALS PLC S
Mar 23, 2026
earnings_calendar
CNTA Q4 2025 Earnings After Market Close — 2026-03-23
Mar 10, 2026
short_interest
FTD: CNTA — 36,906 shares ($1.0M) failed to deliver
Settlement: 20260310, Price: $26.09, FTD Value: $962,877.54, CENTESSA PHARMACEUTICALS PLC S